{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2015_0299791_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"016-656-860-439-543"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8903,"type":"PATENT","title":"Johns Hopkins Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":17938,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8218,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Johns Hopkins Univ\", \"Univ Johns Hopkins\"
Select more for logical variants
Add to collection
Total patents: 12941
Search applicants and owners= \"Johns Hopkins Univ\", \"Univ Johns Hopkins\"
Select more for logical variants
Add to collection
Total patents: 12941
a. providing a sample from the patient;\n
b. measuring white blood cell type counts and the DNA methylation levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises HP1BP3 and TTC9B; and\n
c. determining that the patient is at risk for developing PPD based on the relative DNA methylation levels at the biomarker loci relative to the proportion of differing white blood cell types."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the panel of biomarkers further comprises PABPC1L."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein the PABPC1L biomarker comprises CpG dinucleotides located within the region chr20: 42971786-42971857 on the positive strand (human genome build hg18)."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the HP1BP3 biomarker loci comprises CpG dinucleotides located within the region chr1: 20986708-20986650 on the minus strand (human genome build hg18)."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the TTC9B biomarker loci comprises CpG dinucleotides located at chr19:45416573 on the plus strand (human genome build hg18)."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the panel of biomarkers further comprises OXTR."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17, wherein the OXTR biomarker loci comprises CpG dinucleotides located within the region chr3:8785134-8785171 on the minus strand (human genome build hg18)."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the sample is a blood or serum sample."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the proportion of differing white blood cell types comprises the ratio of monocytes:non-monocytes."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the determining step is performed using a linear model."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["A method for identifying a likelihood of PPD in a patient comprising the steps of:\n
a. providing a sample from the patient;\n
b. measuring white blood cell type counts and DNA methylation levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises HP1BP3 and TTC9B and the white blood cell type counts comprise monocytes and non-monocytes; and\n
c. identifying the patient as likely to develop PPD based on the relative DNA methylation levels at the biomarker loci relative to the ratio of monocytes:non-monocytes."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the panel of biomarkers further comprises PABPC1L."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the HP1BP3 biomarker loci comprises CpG dinucleotides located within the region chr1: 20986708-20986650 on the minus strand (human genome build hg18)."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the TTC9B biomarker loci comprises CpG dinucleotides located at chr19:45416573 on the plus strand (human genome build hg18)."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the sample is a blood or serum sample."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the identifying step is performed using a linear model with DNA methylation at HP1BP3 interacting with the ratio of monocytes:non-monocytes and DNA methylation at TTC9B is included as an additive covariate."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the identifying step is performed using a linear model with DNA methylation at HP1BP3 and TTC9B included as additive covariates and the ratio of monocytes:non-monocytes added as an interacting component."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the identifying step is performed using a linear model and DNA methylation at OXTR is used in place of the ratio of monocytes:non-monocytes."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the OXTR biomarker loci comprises CpG dinucleotides located at chr3:8785134-8785171 on the minus strand (human genome build hg18)."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the identifying step is performed using a linear model and DNA methylation at PABPC1L is used in place of the ratio of monocytes:non-monocytes."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the PABPC1L biomarker comprises CpG dinucleotides located within the region chr20: 42971786-42971857 on the positive strand (human genome build hg18)."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein the addition of the total test score from the Pittsburgh Sleep Quality Index (PSQI) scale taken at the time of sample draw from the patient is used as an additive or interactive covariate in the model to improve prediction accuracy."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein the addition of the total test score from the Clinical Global Impression Scale (CGIS) scale taken at the time of sample draw from the patient is used as an additive or interactive covariate in the model to improve prediction accuracy."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein the addition of the total test score from the Perceived Stress Scale (PSS) scale taken at the time of sample draw from the patient is used as an additive or interactive covariate in the model to improve prediction accuracy."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 33, wherein the addition of DNA methylation biomarker proxies of psychological scale metrics from Table 6 are used in place of test scale metrics."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["A method for diagnosing PPD in a patient comprising the steps of:\n
a. providing a sample from the patient;\n
b. measuring white blood cell type counts and the DNA methylation levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises HP1BP3 and TTC9B and the white blood cell type counts comprise monocytes and non-monocytes; and\n
c. diagnosing the patient as having PPD based on the relative DNA methylation levels at the biomarker loci relative to the proportion of monocytes:non-monocytes."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein an area under the receiver operator characteristic curve analysis is used to identify a likelihood of PPD in the patient."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein linear discriminant analysis is used to predict, determine the risk of developing, identify a likelihood of, or diagnose, PPD."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["A diagnostic kit for determining PPD status in a patient comprising:\n
a. a substrate for collecting a biological sample from the patient; and\n
b. oligonucleotide primers specific for amplifying methylated regions of the biomarkers HP1BP3, TTC9B, OXTR and/or PABPC1L."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The kit of claim 40, wherein the primers are one or more of SEQ ID NOS:1-22."],"number":42,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}